$HYPR

Hyperfine, Inc.

Insider trades
1
0
0

No SEC Form 4 filings for $HYPR in the last 30 days.

See all $HYPR insider activity →
High

Hyperfine, Inc. (HYPR): Results of Operations and Financial Condition

Hyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 hypr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Hyperfine, Inc. Reports Second Quarter 2026 Financial Results GUILFORD, Connecticut, August 6, 2026 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imag

Hyperfine, Inc.: Hyperfine Announces European Launch of Next-Generation Swoop System

Hyperfine (Nasdaq: HYPR) says it has started launching its next-generation Swoop portable MRI system (Model 2) in Europe after CE mark and UKCA approval. The company also reports Model 2 inclusion in UniHA’s procurement listing for France’s public hospitals and plans broader European availability via distribution partners in 2026.

HALE BRETT sold $10K of HYPR

HALE BRETT (CFO and CAO) sold 6,047 shares of Hyperfine, Inc. (HYPR) at $1.65 on 2026-05-26.

HYPR sentiment & insider activity

Over the past 7 days, alphai's AI scored 1 news story mentioning HYPR (Hyperfine, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent HYPR coverage spans financial news, insider activity and earnings.

What's driving HYPR

  • The 8-K provides fresh quarterly datapoints plus full-year revenue and cash-burn guidance, which can drive near-term estimate revisions and positioning.

    SEC EDGAR 8-K · Aug 6, 2026

  • European commercialization of Model 2 is a tangible go-to-market milestone that can support incremental revenue expectations and near-term sentiment.

    finanznachrichten.de · Jul 1, 2026

  • The disclosure is a small, routine insider sale and is unlikely to signal a fundamental change by itself.

    SEC EDGAR · May 27, 2026

  • This is an insider sale with no 10b5-1 plan stated; it may modestly pressure sentiment but lacks fundamental new information.

    SEC EDGAR · May 27, 2026

  • Hyperfine has amended its at-the-market sales agreement to include BTIG as a sales agent, enabling potential future share offerings up to $50 million. This move may lead to increased share supply, potentially exerting downward pressure on the stock price in the short term.

    Investing.com · Dec 30, 2025

alphai scores every news story that mentions HYPR with an AI model for sentiment and relevance, and aggregates insider trades from Hyperfine, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $HYPR

Score
$HYPRHigh

Hyperfine, Inc. (HYPR): Results of Operations and Financial Condition

Hyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 hypr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Hyperfine, Inc. Reports Second Quarter 2026 Financial Results GUILFORD, Connecticut, August 6, 2026 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imag

$HYPRLow

Hyperfine amends at-the-market sales agreement to add BTIG as sales agent

Hyperfine, Inc. (NASDAQ:HYPR) has amended its at-the-market (ATM) issuance sales agreement to include BTIG, LLC as an additional sales agent alongside B. Riley Securities, Inc. This allows Hyperfine to offer and sell up to $50 million of its Class A common stock at its discretion. The company also terminated a previous prospectus supplement under which it had already sold shares for approximately $4.35 million.

Related tickers